Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 2
2009 2
2011 1
2014 1
2015 1
2016 1
2017 3
2018 1
2019 1
2020 1
2022 1
2023 1
2024 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Mixed endometrial carcinoma: is it time to profile the two components separately?
Musettini G, Pretelli P, Giusti A, Cupini S, Coltelli L, De Luca F, De Maio E, Finale C, Masini LC, Soria G, Cirigliano G, Viacava P, Donati S, Valsuani C, Caparello C, Lucchesi M, Furfaro I, Antonelli A, Abate S, Bracco GL, Marrai R, Liut M, Masoni S, Pini C, Mignogna M, Cocuzza P, Ginori A, Vivaldi F, Acconci G, Arrighi G, Barletta MT, Barbara C, Stasi I, Farnesi A, Marini A, Pellino A, Sammarco E, Rosada J, Orlandi F, Cavazzana A, Allegrini G. Musettini G, et al. Among authors: donati s. Front Oncol. 2026 Apr 23;16:1735988. doi: 10.3389/fonc.2026.1735988. eCollection 2026. Front Oncol. 2026. PMID: 42109647 Free PMC article.
Ten tips to reduce gaps in daily oncology practice.
Moscetti L, Ferro A, Angiolini C, Garrone O, Fedele P, Donati S, Gianni L. Moscetti L, et al. Among authors: donati s. Tumori. 2026 Apr 8:3008916261437958. doi: 10.1177/03008916261437958. Online ahead of print. Tumori. 2026. PMID: 41947655
Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial.
Livraghi L, Martella F, Ghilli M, Angiolini C, Magnanini S, Moretti E, Bengala C, Risi E, Molinara E, Pazzagli I, Malorni L, Donati S, Gabellini S, Martignetti A, Giannessi P, Sanna G, Barellini L, Biagioni C, Boni L, Bianchi S, Roncella M, Biganzoli L. Livraghi L, et al. Among authors: donati s. Eur J Cancer. 2024 Dec;213:115108. doi: 10.1016/j.ejca.2024.115108. Epub 2024 Oct 31. Eur J Cancer. 2024. PMID: 39522332 Free article.
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project.
Gori S, De Rose F, Ferro A, Fabi A, Angiolini C, Azzarello G, Cancian M, Cinquini M, Arecco L, Aristei C, Bernardi D, Biganzoli L, Cariello A, Cortesi L, Cretella E, Criscitiello C, De Giorgi U, Carmen De Santis M, Deledda G, Dessena M, Donati S, Dri A, Ferretti G, Foglietta J, Franceschini D, Franco P, Schirone A, Generali D, Gianni L, Giordani S, Grandi G, Cristina Leonardi M, Magno S, Malorni L, Mantoan C, Martorana F, Meattini I, Meduri B, Merlini L, Miglietta F, Modena A, Nicolis F, Palumbo I, Panizza P, Angela Rovera F, Salvini P, Santoro A, Taffurelli M, Toss A, Tralongo P, Turazza M, Valerio M, Verzè M, Vici P, Zamagni C, Curigliano G, Pappagallo G, Zambelli A; Italian Association of Multidisciplinary Oncology Groups (AIGOM). Gori S, et al. Among authors: donati s. Cancer Treat Rev. 2024 Dec;131:102832. doi: 10.1016/j.ctrv.2024.102832. Epub 2024 Oct 5. Cancer Treat Rev. 2024. PMID: 39437511 Free article. Review.
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study.
Arecco L, Latocca MM, Blondeaux E, Riccardi F, Mocerino C, Guarneri V, Mioranza E, Bisagni G, Gasparini E, Puglisi F, Membrino A, Ferro A, Adamo V, Giovanardi F, Tamberi S, Donati S, Landucci E, Biganzoli L, Piccinini S, Pastorino S, de Azambuja E, Poggio F, Lambertini M, Del Mastro L. Arecco L, et al. Among authors: donati s. Breast. 2024 Oct;77:103769. doi: 10.1016/j.breast.2024.103769. Epub 2024 Jul 9. Breast. 2024. PMID: 39043079 Free PMC article.
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients.
Coltelli L, Allegrini G, Orlandi P, Finale C, Fontana A, Masini LC, Scalese M, Arrighi G, Barletta MT, De Maio E, Banchi M, Fini E, Guidi P, Frenzilli G, Donati S, Giovannelli S, Tanganelli L, Salvadori B, Livi L, Meattini I, Pazzagli I, Di Lieto M, Pistelli M, Casadei V, Ferro A, Cupini S, Orlandi F, Francesca D, Lorenzini G, Barellini L, Falcone A, Cosimi A, Bocci G. Coltelli L, et al. Among authors: donati s. NPJ Breast Cancer. 2022 Mar 21;8(1):33. doi: 10.1038/s41523-022-00400-6. NPJ Breast Cancer. 2022. PMID: 35314692 Free PMC article.
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.
Biganzoli L, Cinieri S, Berardi R, Pedersini R, McCartney A, Minisini AM, Caremoli ER, Spazzapan S, Magnolfi E, Brunello A, Risi E, Palumbo R, Leo S, Colleoni M, Donati S, De Placido S, Orlando L, Pistelli M, Parolin V, Mislang A, Becheri D, Puglisi F, Sanna G, Zafarana E, Boni L, Mottino G. Biganzoli L, et al. Among authors: donati s. Breast Cancer Res. 2020 Aug 5;22(1):83. doi: 10.1186/s13058-020-01319-1. Breast Cancer Res. 2020. PMID: 32758299 Free PMC article. Clinical Trial.
21 results